Front DD Block

My name is Morgan. I am a yogi who seeks to balance work and family as I try to cure cancer.

I am H3 >> Read my story

My name is Markus. I am a medical doctor and a CEO who has seen personalized cancer treatments evolve from myth, to clinical studies, to actual products.

I am H3 >> Read my story

An innovative, freethinking environment fosters teamwork and creative problem solving, and drives our quest to personalize cancer treatments.

My name is Lihua. I am a computational biologist, an engineer, and a mother who seeks patterns that present visually - whether in genomics sequencing or in origami.

I am H3 >> Read my story

My name is James. I am a normal guy with heart-pumping hobbies who also keeps H3 Biomedicine’s labs well equipped. For me, there is nothing more exciting than being part of this team.

I am H3 >> Read my story

My name is Dominic. I am a scientist, a husband, and a father. I whistle, I drink tea, and I synthesize molecules that target cancer.

I am H3 >> Read my story

Fluorescent microscopy helps drive drug discovery, bringing hope to those affected by cancer. I am Rachel and I am a scientist who believes in the power of hope.

I am H3 >> Read my story

I mix my chemistry proficiencies with powerful insights from my diverse scientific team. I also happen to be a curious scientist who loves to cook.

I am H3 >> Read my story

I am H3

At H3 Biomedicine Inc., each team member has a unique role to play in the quest to develop new cancer drugs. Yet we also operate in the spirit of the collaboration and camaraderie encouraged by the corporate culture. We are dedicated and passionate individuals who recognize that our potential as a team is much greater than if any one of us was working alone.

H3 Biomedicine Inc. is a unique oncology discovery enterprise guided by the vision of our scientific founders and partnered with Eisai, Inc. Headquartered in Cambridge, MA, H3 Biomedicine is integrating human cancer genomics with next-generation synthetic organic chemistry and tumor biology capabilities to generate a large library of novel small-molecule drugs to treat cancer.